Time to reconsider the role of sentinel lymph node biopsy in melanoma

被引：23

作者：

Bigby, Michael ^{[1
,2
]}

Zagarella, Samuel ^{[3
]}

Sladden, Michael ^{[4
]}

Popescu, Catalin M. ^{[5
]}

机构：

[1] Harvard Med Sch, Dept Dermatol, Boston, MA 02215 USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Univ Sydney, Dept Dermatol, Sch Med, Sydney, NSW, Australia

[4] Univ Tasmania, Dept Med, Sch Med, Launceston, Tas, Australia

[5] Carol Davila Univ Med & Pharm, Bucharest, Romania

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 80卷 / 04期

关键词：

Breslow thickness; hazard ration; immediate completion lymph node dissection; melanoma; multicenter selective lymphadenectomy trial; prognosis; sentinel lymph node biopsy; survival; PROGNOSTIC VALUE; SURVIVAL;

D O I：

10.1016/j.jaad.2018.11.026

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specific survival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completion lymph node dissection compared with wide excision and observation for patients with positive sentinel nodes. These results make SLNB solely a staging procedure. The role of SLNB in the management of patients with melanoma deserves reappraisal. The potential marginal benefit of SLNB beyond the clinical and pathologic features of the melanoma has not been well studied. The use of sentinel lymph node status alone to accept and stratify patients into trials or to receive adjuvant treatment is not rational.

引用

页码：1168 / 1171

页数：4

共 20 条

[1] Sentinel lymph node biopsy in melanoma [J].

Bigby, Michael ;

Popescu, Catalin .

BMJ-BRITISH MEDICAL JOURNAL, 2015, 351

[2]

Coit D, 2017, 9 WORLD C MEL BRISB

[3] The Enigma of Regional Lymph Nodes in Melanoma [J].

Coit, Daniel .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) :2280-2281

[4]

Coliron B, SENTINEL NODE BIOPSY

[5] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

[6] Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma [J].

Faries, M. B. ;

Thompson, J. F. ;

Cochran, A. J. ;

Andtbacka, R. H. ;

Mozzillo, N. ;

Zager, J. S. ;

Jahkola, T. ;

Bowles, T. L. ;

Testori, A. ;

Beitsch, P. D. ;

Hoekstra, H. J. ;

Moncrieff, M. ;

Ingvar, C. ;

Wouters, M. W. J. M. ;

Sabel, M. S. ;

Levine, E. A. ;

Agnese, D. ;

Henderson, M. ;

Dummer, R. ;

Rossi, C. R. ;

Neves, R. I. ;

Trocha, S. D. ;

Wright, F. ;

Byrd, D. R. ;

Matter, M. ;

Hsueh, E. ;

MacKenzie-Ross, A. ;

Johnson, D. B. ;

Terheyden, P. ;

Berger, A. C. ;

Huston, T. L. ;

Wayne, J. D. ;

Smithers, B. M. ;

Neuman, H. B. ;

Schneebaum, S. ;

Gershenwald, J. E. ;

Ariyan, C. E. ;

Desai, D. C. ;

Jacobs, L. ;

McMasters, K. M. ;

Gesierich, A. ;

Hersey, P. ;

Bines, S. D. ;

Kane, J. M. ;

Barth, R. J. ;

McKinnon, G. ;

Farma, J. M. ;

Schultz, E. ;

Vidal-Sicart, S. ;

Hoefer, R. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) :2211-2222

[7] No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report [J].

Faries, M. B. ;

Cochran, A. J. ;

Elashoff, R. M. ;

Thompson, J. F. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (03) :566-573

[8] Prognostic Value of Sentinel Lymph Node Biopsy Compared with that of Breslow Thickness: Implications for Informed Consent in Patients with Invasive Melanoma [J].

Freeman, Scott R. ;

Gibbs, Bethany B. ;

Brodland, David G. ;

Zitelli, John A. .

DERMATOLOGIC SURGERY, 2013, 39 (12) :1800-1812

[9] Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].

Gershenwald, JE ;

Thompson, W ;

Mansfield, PF ;

Lee, JE ;

Colome, MI ;

Tseng, CH ;

Lee, JJ ;

Balch, CM ;

Reintgen, DS ;

Ross, MI .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983

[10]

Grob J-J, 2015, MELANOMA LETT, V33, P6

← 1 2 →